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ABSTRACT 
 
Since the introduction of vaccination against hepatitis B virus (HBV) infection in South 
Africa, at least one case of infection despite vaccination has occurred. The purpose of this 
study was to determine whether this infection was the result of mutations within the region 
of the surface (S) gene encoding the a determinant epitopes of the hepatitis B surface 
antigen, which permitted viral vaccine-escape. HBV DNA was extracted from the serum 
and liver tissue of the patient and amplified within the complete 3 215 bp genome and S 
gene, respectively. Following cloning, sequencing revealed a minor population displaying 
unique or uncommon S gene mutations that resulted in C138R, C139R, K141R, P142L, 
T143A, N146D, and T148A amino acid substitutions in the clones from the serum, and 
C139Y and D144N in the clones from the liver. Such isolates may represent South African 
HBV vaccine-escape mutants that caused chronic infection in the host prior to their 
reversion to wild-type.         
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Chapter 1:   INTRODUCTION 
 
Hepatitis B, a serious liver disease induced by the hepatitis B virus (HBV), is a major 
global public health problem with the virus infecting over two billion people, of which 
approximately 387 million are chronically infected [World Health Organisation, 2002]. 
Since the development of hepatitis B vaccines, the number of newly acquired HBV 
infections has decreased substantially, to a very small fraction of the number acquired prior 
to vaccine administration. Nevertheless, vaccination does not protect all individuals from 
infection, because of either weak immune responses from the host or viral mutations, both 
of which allow vaccine escape of the virus. 
 
  
1.1 HEPATITIS B VIRUS 
 
1.1.1 History 
 
Epidemic jaundice was first described by Hippocrates in the fifth century BC, when he was 
undoubtedly referring to individuals infected with hepatitis B virus and other agents 
capable of infecting the liver [Mahoney, 1999]. Epidemics of jaundice have continued to 
occur throughout history, particularly during wars in the 19th and 20th centuries [Mahoney, 
1999]. 
 
The existence of a form of hepatitis that was parenterally transmitted by direct inoculation 
of blood or blood products was first documented by Lurman in Bremen, Germany, in 1883, 
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during a smallpox vaccination campaign that utilised contaminated human lymph [Lurman, 
1885]. Early in the 20th century, further outbreaks of parenterally acquired hepatitis 
occurred in various risk groups including patients who attended clinics for venereal 
diseases, diabetes, and tuberculosis; those who received blood transfusions; persons 
inoculated with mumps or measles serum; and military personnel who received yellow 
fever vaccines during World War II [Neefe et al., 1946; Mahoney, 1999]. 
 
Studies conducted during the 1930s and 1940s provided convincing evidence of a viral 
cause for hepatitis, with at least two etiologic agents [MacCallum and Bauer, 1944; 
Havens, 1946]. Subsequently, in 1947, MacCallum and Bauer (1947) proposed the 
nomenclature of hepatitis A for infectious hepatitis and hepatitis B for “homologous 
serum” hepatitis, terms which have since been adopted by the World Health Organisation 
(WHO) Committee on Viral Hepatitis. The distinctive seroepidemiologic features of 
hepatitis A and B were finally firmly established in a series of studies by Krugman and 
colleagues (1967) at the Willowbrook State School, New York, in the 1960s. 
 
The viral agent associated with hepatitis B was first isolated during serological studies 
conducted independently by Prince et al. (1964) and Blumberg et al. (1965). In searching 
for serum protein polymorphisms linked to diseases, Blumberg and colleagues identified 
an antigen – termed Australia (Au) antigen – in serum from patients with leukaemia, 
leprosy, and hepatitis, although the relationship of the antigen to hepatitis was not fully 
recognised until 1967. Prince (1968) subsequently established that the Au antigen occurred 
specifically in the serum of hepatitis B patients, and in 1973 the antigen was renamed the 
hepatitis B surface antigen (HBsAg) by the WHO. 
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In 1970, Dane and colleagues (1970) were the first to detect complete hepatitis B virions, 
or Dane particles. The 42 nm double-shelled spheres consisted of an outer envelope 
composed of HBsAg and an inner core containing hepatitis B core antigen (HBcAg) and 
endogenous DNA. A third antigen related to infectivity, designated hepatitis B e antigen 
(HBeAg), was subsequently described in 1972 by Magnius and Espmark (1972). 
 
In 1975, following these important breakthroughs in hepatitis research, hepatitis B vaccine 
studies were initiated using plasma-derived highly purified HBsAg particles, as it was 
found that antibodies targeting HBsAg were the neutralising antibodies for infectious HBV 
[Hollinger et al., 1974]. The safety and efficacy of these vaccines have since been 
established and continue to be maintained. 
 
 
 
1.1.2 Natural History and Pathogenesis 
 
The hepatitis B virus is one of the most successful viral pathogens of humans because of 
the nature of its infections. Although the hepatocytes are the principal site of viral 
infection, pathological features of HBV infection have been identified in extrahepatic 
tissues such as the kidneys, lymph nodes, spleen, gonads, thyroid gland, adrenal glands, 
and bone marrow [Hollinger, 1996; Hilleman, 2003]. The liver plays an essential role in 
protein, carbohydrate, and lipid metabolism, energy storage and conversion, blood 
homeostasis, chemical detoxification, and immunity to microbial infections [Seeger and 
Mason, 2000]. Disruption of this organ by HBV infection therefore leads to a varying array 
of acute and chronic disease manifestations. 
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The consequences of acute HBV infection are highly variable, ranging from subclinical 
and asymptomatic to clinically apparent disease [Robinson, 1994]. The incubation period 
of hepatitis B – the time from infection to the onset of signs or symptoms – ranges from six 
weeks to six months, with the development of clinical symptoms being highly dependent 
on the age of the host [Mahoney, 1999]. Clinical manifestations do not generally occur in 
neonates, while infection produces typical illness in only 5 to 15% of children aged one to 
five years [McMahon et al., 1985; Mahoney, 1999]. In contrast, 33 to 50% of older 
children and adults develop symptomatic infections, varying in severity from mild to 
fulminant hepatitis with extensive liver necrosis (Figure 1.1) [Mahoney, 1999]. The 
clinical signs and symptoms of acute HBV infection that result from hepatic inflammation, 
include fever, jaundice, malaise, nausea, vomiting, abdominal pain, and increased serum 
levels of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) [Francois et al., 2001]. Fulminant hepatitis, appearing suddenly, rapidly, and with 
great intensity, occurs in 1 to 2% of acute infections and has a case-fatality ratio of 63 to 
93% [Mahoney, 1999]. 
 
The risk of developing chronic HBV infection – defined as the presence of HBsAg in the 
serum for longer than six months – decreases with age: approximately 90% of infected 
neonates, 50% of infants, 30% of children, and 10% of infected adults become HBV 
carriers [Hilleman, 2003]. Individuals with chronic hepatitis B infections generally have 
one of three types of disease – chronic persistent hepatitis, chronic active hepatitis, or 
cirrhosis [Mahoney, 1999]. The degree of histological injury is often not reflected by the 
symptoms, such that persons with severe chronic liver disease may remain asymptomatic 
until late in the course of their illness [Mahoney, 1999]. Chronic active hepatitis leads to 
the development of liver fibrosis and often to cirrhosis, an irreversible condition in which
  5 
 
Figure 1.1   Schematic representation of the pathogenesis of hepatitis B virus infection in adults, indicating the percentage of infections that 
progress to various forms of the disease [Modified from Feitelson, 1994]. 
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regenerative nodules and fibrosis cause severe liver injury [Mahoney, 1999; Ganem and 
Prince, 2004]. Because of its stimulating effect on hepatocyte regeneration, cirrhosis may 
subsequently lead to the development of hepatocellular carcinoma (HCC), a malignant 
liver tumour that typically appears 25 to 30 years after the onset of infection [Mahoney, 
1999] and culminates in the death of the individual (Figure 1.1).  
 
The pathogenesis of hepatitis B is extremely complex [Hilleman, 2003]. Although HBV 
causes hepatitis B, the virus itself is not directly cytopathic in humans and therefore causes 
only limited damage to the liver [Francois et al., 2001]. The clinical effects of the disease 
are, instead, the result of the destruction of infected hepatocytes by the host immune 
defence system [Hollinger, 1996]. Variations in the clinical outcome of HBV infection are 
therefore caused by differences in the host response and, possibly, by mutations in the 
HBV genome that result in the production of variant viruses [Feitelson, 1994; Kidd-
Ljunggren, 1996]. 
 
Although the mechanism of liver injury in acute and chronic hepatitis B is not completely 
defined [Robinson, 1994], it is known that aggressive immune responses, involving both 
major histocompatibility complex (MHC) class II-restricted, CD4+ helper cells and MHC 
class I-restricted, CD8+ cytotoxic T-lymphocytes [Ganem and Prince, 2004], result in 
symptomatic acute hepatitis and viral clearance, while non-aggressive host responses that 
reflect weak T-cell-mediated immune responses lead to an asymptomatic chronic viral 
carrier state [Hilleman, 2003].   
 
Of the approximately 387 million chronic carriers of HBV worldwide, 15-40% eventually 
develop cirrhosis, liver failure, or HCC [Lok, 2002]. In addition, HBV infection results in 
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500 000 to 1.2 million deaths each year, making it the tenth leading cause of death 
worldwide, while HCC is the fifth most common cancer, killing 300 000 to 500 000 people 
per year [Lavanchy, 2004].  
 
 
 
1.1.3 Epidemiology 
 
Present mainly in blood, saliva, and semen, hepatitis B virus is transmitted horizontally by 
percutaneous or permucosal exposure to infectious blood and body fluids, or perinatally 
from an infected mother to her infant during the perinatal period [Mahoney, 1999; Alter, 
2003]. As a highly resilient virus, HBV is resistant to breakdown and can therefore also 
survive outside the body for longer than a week [Alter, 2003; Lavanchy, 2004]. 
 
The prevalence of HBV infection and patterns of transmission vary greatly in different 
geographic regions of the world and in different population subgroups (Figure 1.2) 
[Mahoney, 1999; Lavanchy, 2004]. Approximately 45% of the global population live in 
areas where the prevalence of chronic HBV infection is high (8% or more of the 
population is HBsAg positive), 43% live in areas with moderate prevalence (2 to 7% of the 
population is HBsAg positive), and 12% live in areas of low endemicity (less than 2% of 
the population is HBsAg positive) [Mahoney, 1999]. 
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Figure 1.2   World map showing geographic distribution of chronic HBV infection 
[Strauss and Strauss, 2002]. 
 
 
In areas of high endemicity – including sub-Saharan Africa, most of Asia and the Middle 
East, the Amazon Basin of South America, the Pacific Islands, and other special population 
groups such as Native Alaskans, Australian Aborigines, and Maoris in New Zealand – the 
most common source of infection is through perinatal transmission or through infection 
acquired horizontally during early childhood [Mahoney, 1999; de Franchis et al., 2003].  
The high proportion of infectious HBV carriers explains the high rate of perinatal and 
childhood transmission, which perpetuate the high prevalence of HBV infections in these 
endemic countries [de Franchis et al., 2003]. Thus, the lifetime risk of HBV infection in 
such highly endemic areas is greater than 60% [Mahoney, 1999]. 
 
In areas of moderate endemicity, such as North Africa, some of the Middle East, the 
southern parts of Eastern and Central Europe, the USSR, the Indian subcontinent, and part 
of Brazil, the current important modes of HBV transmission are needle sharing among 
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injecting drug users, nosocomial (hospital) transmission, tattooing, and body piercing [de 
Franchis et al., 2003]. In contrast to highly endemic countries, the lifetime risk of HBV 
infection in intermediate areas is 20 to 60% [Mahoney, 1999], with over 95% of new 
infections being acquired during adulthood [de Franchis et al., 2003]. 
 
Areas of low HBV endemicity include Northwest Europe, Australia, and North America 
[Mahoney, 1999; de Franchis et al., 2003]. In these regions, most HBV infections are 
acquired by horizontal transmission in early adulthood: through needle sharing among 
injecting drug users and through sexual contacts [de Franchis et al., 2003; Lavanchy, 
2004]. Other rare sources of infection include contaminated surgical instruments, needle-
stick injuries by hospital personnel, and blood transfusions [Alter, 2003]. The lifetime risk 
of infection in these developed countries is less than 20%, with most infections occurring 
amongst well-defined risk groups [Mahoney, 1999]. 
 
In South Africa, a country with intermediate HBV endemicity and pockets of high 
endemicity [Dusheiko et al., 1989a; Dusheiko et al., 1989b], more than 70% of the 
population has been exposed to HBV and approximately four million (almost entirely 
black people) are carriers [Kew, 1996; Tsebe et al., 2001]. Of these, an estimated 14 000 to 
18 000 people die per annum [Mphahlele et al., 2002]. The majority of black carriers of 
HBV are infected in early childhood by horizontal transmission, probably by infected 
blood or saliva through skin abrasions, lesions, and bites, and tribal scarification or 
tattooing with unsterilised sharp instruments [Kew, 1996; Kiire, 1996]. Their main sources 
of infection are other family members, such as highly infectious siblings aged between one 
and five years, and playmates of the same age [Kew, 1996]. In contrast to it being the 
major source of HBV infection in Southeast Asia, maternal-infant perinatal infection is 
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relatively uncommon in black Africans [Kew, 1996]. The carrier rate of HBV differs 
regionally in South Africa, with higher rates of infection in rural areas (5 to 15%) than in 
urban areas (less than 5%) [Dusheiko et al., 1989a; Dusheiko et al., 1989b]; however, this 
difference cannot be explained by socioeconomic inequalities [Mphahlele et al., 2002]. 
 
 
 
1.1.4 Classification 
 
The hepatitis B virus (HBV) was the first member to be discovered within the family of 
viruses designated the Hepadnaviridae (hepatotropic DNA viruses) [van Regenmortel et 
al., 2000]. This family was subsequently divided into two groups, the orthohepadnaviruses 
(mammalian hepadnaviruses), of which HBV is the prototype member, and the 
avihepadnaviruses (avian hepadnaviruses) [van Regenmortel et al., 2000].  
 
Hepadnaviruses share many epidemiologic and biological features. As their names imply, 
all hepadnaviruses are hepatotropic and can cause hepatitis in their native host, and all 
exhibit a narrow host range that may be determined by the identity of the host hepatocyte 
receptor [Strauss and Strauss, 2002]. However, in contrast to orthohepadnaviruses, which 
mostly exhibit horizontal transmission, avihepadnaviruses are transmitted vertically 
[Strauss and Strauss, 2002]. 
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1.1.5 Virion Structure 
 
Each infectious HBV virion, or Dane particle, measuring 42 nm in diameter, consists of a 
spherical outer envelope that is 7 nm thick and encloses a 27-34 nm electron-dense, 
icosahedral core particle containing the viral nucleic acid and DNA polymerase (Figure 
1.3) [Hollinger, 1996]. The envelope is composed of host-derived lipids, in which three 
types of different sized viral surface glycoproteins are embedded [Seeger, 1994]. In the 
blood of HBV-infected patients, titres of Dane particles can range from less than 104/ml to 
greater than 109/ml [Ganem, 1996]. 
 
In addition to complete Dane particles, sera of HBV infected individuals also contain two 
distinct subviral particles: spherical 20 nm particles and tubular or filamentous particles of 
20 nm diameter and variable length (Figure 1.3) [Hollinger, 1996]. Both such particles are 
composed exclusively of viral surface glycoproteins (~70%) and host-derived lipids, such 
as phospholipids, cholesterol, and triglycerides [Ganem, 1996]. However, unlike Dane 
particles, subviral particles lack nucleic acid and are thus non-infectious, although they 
remain highly immunogenic [Ganem, 1996]. The most abundant of the three types of HBV 
particles, 20 nm spheres can reach titres as high as 1013/ml, while filaments can reach titres 
of 1011/ml [Ganem, 1996; Locarnini, et al., 2003]. As such, subviral particles comprise 
over 90% of the total HBV particles in the sera of infected individuals [Paran et al., 2003]. 
This excess of viral surface antigen particles is thought to adsorb neutralising antibodies, 
thereby helping to shield the infectious virions from host defences [Ganem, 1996]. 
 
